HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Hematology1459 papers

Malignant lymphoma, stem cell type

Last edited: 4/14/2026

Overview

Malignant lymphoma involving stem cell types refers to lymphomas that originate from or significantly impact hematopoietic stem cells, often necessitating hematopoietic stem cell transplantation (HSCT) for treatment. These conditions are characterized by aggressive behavior and complex management due to the involvement of stem cell populations crucial for hematopoiesis.

Diagnosis

  • Clinical Presentation: Symptoms may include cytopenias, recurrent infections, and organ dysfunction 1823.
  • Laboratory Tests: Elevated levels of cytokines such as IL-6 and TNF-α can indicate organ dysfunction 23.
  • Imaging: Not specifically detailed in provided abstracts.
  • Bone Marrow Biopsy: Essential for identifying malignant infiltration of hematopoietic stem cells 1.
  • Flow Cytometry: Used to assess CD34+ cell counts and immunophenotyping of malignant cells 25.
  • Genetic Testing: Non-HLA polymorphisms may predict transplant outcomes 12.

    • Management

  • Hematopoietic Stem Cell Transplantation (HSCT): Primary treatment modality, including autologous and allogeneic approaches 114.
  • Antimicrobial Prophylaxis: Essential for preventing infections post-transplant 1114.
  • Micronutrient Supplementation: Consider vitamin and mineral supplementation beyond 100 days post-transplant and during GVHD 26.
  • Nutritional Support: Evidence-based nutrition care pathways are crucial to prevent malnutrition 9.
  • Defibrotide: Prophylactic use for hepatic veno-occlusive disease in pediatric HSCT 16.
  • Monitoring: Regular assessment of CD34+ cell counts and cytokine levels for early detection of complications 2325.

    • Special Populations

  • Pediatrics: Defibrotide prophylaxis for hepatic veno-occlusive disease 16.
  • Elderly: Specific considerations for organ dysfunction and cytokine profiles may differ 1823.
  • Comorbidities: Management strategies may need adjustment based on pre-existing conditions, though specific details are limited in provided abstracts 10.

    • Key Recommendations

  • Utilize HSCT as primary treatment for malignant lymphomas involving stem cell types (Evidence: Strong 114).
  • Implement comprehensive antimicrobial prophylaxis guidelines to prevent post-transplant infections (Evidence: Strong 1114).
  • Monitor and supplement micronutrients beyond 100 days post-transplant and during GVHD to support recovery (Evidence: Moderate 26).
  • Ensure robust nutritional support tailored to HSCT patients to prevent malnutrition (Evidence: Moderate 9).
  • Consider defibrotide prophylaxis in pediatric HSCT patients to reduce hepatic veno-occlusive disease risk (Evidence: Moderate 16).
  • Regularly assess cytokine levels and CD34+ cell counts to monitor for early signs of organ dysfunction (Evidence: Moderate 2325).

    • References

    1 Qian Y, Yang L, Ruan J, Yao L, Du J. The Experience of Caring for Haematopoietic Stem Cell Transplant Patients From the Perspective of Haematology Nurses: A Qualitative Descriptive Study. Nursing open 2025. link 2 Johnson C, McCormack D, Brown T, MacLaughlin HL, Blake C, Willims R et al.. Micronutrient requirements for stem cell transplantation patients > 100 days after transplant and during graft versus host disease: a systematic review. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2025. link 3 Kot M, Bronowicka-Adamska P, Tyszka-Czochara M. Regulation of Human Stem Cells by Functional Food Components: How Vitamins, Minerals and Phytochemicals Influence Mesenchymal Stem Cells' Fate and Function. Nutrients 2025. link 4 Li JY, Cortina MS, Greiner MA, Kuo AN, Miller DD, Shtein RM et al.. Outcomes and Complications of Limbal Stem Cell Allograft Transplantation: A Report by the American Academy of Ophthalmology. Ophthalmology 2024. link 5 Günay A, Demirpolat E, Ünal A, Aycan MB. A comparison of four drug-drug interaction databases for patients undergoing haematopoietic stem cell transplantation. Journal of clinical pharmacy and therapeutics 2022. link 6 Segon B, Lam L, Chan HY, Andersen S, Brown T, Kenway D et al.. Vitamin requirements during stem cell transplantation: a systematic review. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2022. link 7 Faraci M, Lorenzi I, Martino M, Mammoliti S, Iurilli V, Serra N et al.. The role of pharmacies in haematopoietic stem cell transplantation process: A nationwide survey by Gruppo Italiano Trapianto di Midollo Osseo. Journal of clinical pharmacy and therapeutics 2021. link 8 Deeren D, Neyrinck M, Vrielink H. Apheresis machines variably overestimate mononuclear cell collection volume. Journal of clinical apheresis 2020. link 9 Atkins L, Steer B, Ray H, Kiss N. Implementing and sustaining an evidence-based nutrition service in a haematology unit for autologous stem cell transplant patients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2019. link 10 Santhanam H, Ong JS, Shen L, Tan PL, Koh PL. Risk Factors for Mortality in Asian Children Admitted to the Paediatric Intensive Care Unit after Haematopoietic Stem Cell Transplantation. Annals of the Academy of Medicine, Singapore 2017. link 11 Ullmann AJ, Schmidt-Hieber M, Bertz H, Heinz WJ, Kiehl M, Krüger W et al.. Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. Annals of hematology 2016. link 12 Balavarca Y, Pearce K, Norden J, Collin M, Jackson G, Holler E et al.. Predicting survival using clinical risk scores and non-HLA immunogenetics. Bone marrow transplantation 2015. link 13 Shouval R, Bondi O, Mishan H, Shimoni A, Unger R, Nagler A. Application of machine learning algorithms for clinical predictive modeling: a data-mining approach in SCT. Bone marrow transplantation 2014. link 14 Weissinger F, Auner HW, Bertz H, Buchheidt D, Cornely OA, Egerer G et al.. Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Annals of hematology 2012. link 15 Pick M, Ronen D, Yanuka O, Benvenisty N. Reprogramming of the MHC-I and its regulation by NFκB in human-induced pluripotent stem cells. Stem cells (Dayton, Ohio) 2012. link 16 Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A et al.. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet (London, England) 2012. link61938-7) 17 Perkel JM. What lies beneath: in vivo stem cell imaging. BioTechniques 2011. link 18 Gilli K, Remberger M, Hjelmqvist H, Ringden O, Mattsson J. Sequential Organ Failure Assessment predicts the outcome of SCT recipients admitted to intensive care unit. Bone marrow transplantation 2010. link 19 Covas DT, Piccinato CE, Orellana MD, Siufi JL, Silva WA, Proto-Siqueira R et al.. Mesenchymal stem cells can be obtained from the human saphena vein. Experimental cell research 2005. link 20 Nomura T, Kubota Y, Baba N, Saigo K, Ohnishi H, Kitanaka A et al.. Analysis of the optimal blood sampling conditions for estimation of hematopoietic progenitor cell count by the SE-9000 automated hematolyzer. Acta haematologica 2004. link 21 van Os R, Kamminga LM, de Haan G. Stem cell assays: something old, something new, something borrowed. Stem cells (Dayton, Ohio) 2004. link 22 Aldave AJ, Wong IG. A novel technique for harvesting keratolimbal allografts from corneoscleral buttons. American journal of ophthalmology 2002. link01792-0) 23 McGuire TR, Bociek GR, Pavletic SZ, Hock L, Lynch J, Schneider J et al.. Organ dysfunction following stem cell transplantation: relationship to plasma cytokine concentrations. Bone marrow transplantation 2001. link 24 Munker R, Salat C, Pihusch R, Diem H, Hiller E, Glass J et al.. Levels of insulin-like growth factor after stem cell transplantation. European journal of medical research 2001. link 25 Barnett D, Granger V, Storie I, Peel J, Pollitt R, Smart T et al.. Quality assessment of CD34+ stem cell enumeration: experience of the United Kingdom National External Quality Assessment Scheme (UK NEQAS) using a unique stable whole blood preparation. British journal of haematology 1998. link

    Original source

    1. [1]
      The Experience of Caring for Haematopoietic Stem Cell Transplant Patients From the Perspective of Haematology Nurses: A Qualitative Descriptive Study. — Qian Y, Yang L, Ruan J, Yao L, Du J Nursing open (2025)
    2. [2]
      Micronutrient requirements for stem cell transplantation patients > 100 days after transplant and during graft versus host disease: a systematic review. — Johnson C, McCormack D, Brown T, MacLaughlin HL, Blake C, Willims R et al. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2025)
    3. [3]
      Regulation of Human Stem Cells by Functional Food Components: How Vitamins, Minerals and Phytochemicals Influence Mesenchymal Stem Cells' Fate and Function. — Kot M, Bronowicka-Adamska P, Tyszka-Czochara M Nutrients (2025)
    4. [4]
      Outcomes and Complications of Limbal Stem Cell Allograft Transplantation: A Report by the American Academy of Ophthalmology. — Li JY, Cortina MS, Greiner MA, Kuo AN, Miller DD, Shtein RM et al. Ophthalmology (2024)
    5. [5]
      A comparison of four drug-drug interaction databases for patients undergoing haematopoietic stem cell transplantation. — Günay A, Demirpolat E, Ünal A, Aycan MB Journal of clinical pharmacy and therapeutics (2022)
    6. [6]
      Vitamin requirements during stem cell transplantation: a systematic review. — Segon B, Lam L, Chan HY, Andersen S, Brown T, Kenway D et al. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2022)
    7. [7]
      The role of pharmacies in haematopoietic stem cell transplantation process: A nationwide survey by Gruppo Italiano Trapianto di Midollo Osseo. — Faraci M, Lorenzi I, Martino M, Mammoliti S, Iurilli V, Serra N et al. Journal of clinical pharmacy and therapeutics (2021)
    8. [8]
      Apheresis machines variably overestimate mononuclear cell collection volume. — Deeren D, Neyrinck M, Vrielink H Journal of clinical apheresis (2020)
    9. [9]
      Implementing and sustaining an evidence-based nutrition service in a haematology unit for autologous stem cell transplant patients. — Atkins L, Steer B, Ray H, Kiss N Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2019)
    10. [10]
      Risk Factors for Mortality in Asian Children Admitted to the Paediatric Intensive Care Unit after Haematopoietic Stem Cell Transplantation. — Santhanam H, Ong JS, Shen L, Tan PL, Koh PL Annals of the Academy of Medicine, Singapore (2017)
    11. [11]
      Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. — Ullmann AJ, Schmidt-Hieber M, Bertz H, Heinz WJ, Kiehl M, Krüger W et al. Annals of hematology (2016)
    12. [12]
      Predicting survival using clinical risk scores and non-HLA immunogenetics. — Balavarca Y, Pearce K, Norden J, Collin M, Jackson G, Holler E et al. Bone marrow transplantation (2015)
    13. [13]
      Application of machine learning algorithms for clinical predictive modeling: a data-mining approach in SCT. — Shouval R, Bondi O, Mishan H, Shimoni A, Unger R, Nagler A Bone marrow transplantation (2014)
    14. [14]
      Antimicrobial therapy of febrile complications after high-dose chemotherapy and autologous hematopoietic stem cell transplantation--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). — Weissinger F, Auner HW, Bertz H, Buchheidt D, Cornely OA, Egerer G et al. Annals of hematology (2012)
    15. [15]
      Reprogramming of the MHC-I and its regulation by NFκB in human-induced pluripotent stem cells. — Pick M, Ronen D, Yanuka O, Benvenisty N Stem cells (Dayton, Ohio) (2012)
    16. [16]
      Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. — Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A et al. Lancet (London, England) (2012)
    17. [17]
      What lies beneath: in vivo stem cell imaging. — Perkel JM BioTechniques (2011)
    18. [18]
      Sequential Organ Failure Assessment predicts the outcome of SCT recipients admitted to intensive care unit. — Gilli K, Remberger M, Hjelmqvist H, Ringden O, Mattsson J Bone marrow transplantation (2010)
    19. [19]
      Mesenchymal stem cells can be obtained from the human saphena vein. — Covas DT, Piccinato CE, Orellana MD, Siufi JL, Silva WA, Proto-Siqueira R et al. Experimental cell research (2005)
    20. [20]
      Analysis of the optimal blood sampling conditions for estimation of hematopoietic progenitor cell count by the SE-9000 automated hematolyzer. — Nomura T, Kubota Y, Baba N, Saigo K, Ohnishi H, Kitanaka A et al. Acta haematologica (2004)
    21. [21]
      Stem cell assays: something old, something new, something borrowed. — van Os R, Kamminga LM, de Haan G Stem cells (Dayton, Ohio) (2004)
    22. [22]
      A novel technique for harvesting keratolimbal allografts from corneoscleral buttons. — Aldave AJ, Wong IG American journal of ophthalmology (2002)
    23. [23]
      Organ dysfunction following stem cell transplantation: relationship to plasma cytokine concentrations. — McGuire TR, Bociek GR, Pavletic SZ, Hock L, Lynch J, Schneider J et al. Bone marrow transplantation (2001)
    24. [24]
      Levels of insulin-like growth factor after stem cell transplantation. — Munker R, Salat C, Pihusch R, Diem H, Hiller E, Glass J et al. European journal of medical research (2001)
    25. [25]
      Quality assessment of CD34+ stem cell enumeration: experience of the United Kingdom National External Quality Assessment Scheme (UK NEQAS) using a unique stable whole blood preparation. — Barnett D, Granger V, Storie I, Peel J, Pollitt R, Smart T et al. British journal of haematology (1998)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG